MM-235: Outcomes of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Followed by High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDCT/ASCT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Abdallah, Al‐Ola; Mohyuddin, Ghulam Rehman; Mahmoudjafari, Zahra; Atrash, Shebli; Kawsar, Hameem I.; Sigle, Monia; Shune, Leyla; McGuirk, Joseph P.; Ganguly, Siddhartha

doi:10.1016/s2152-2650(20)30946-0

Clinical Lymphoma Myeloma and Leukemia

2020

DOI: 10.1016/s2152-2650(20)30946-0

|View full text |Cite

MM-235: Outcomes of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Followed by High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDCT/ASCT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Al‐Ola Abdallah

Ghulam Rehman Mohyuddin

Zahra Mahmoudjafari

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

MM-235: Outcomes of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Followed by High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDCT/ASCT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Cited by 1 publication

References 0 publications

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Contact Info

Product

Resources

About